Abstract
The management of type 2 diabetes is rapidly changing to reflect increasing numbers of therapeutic agents and the clinical trials supporting their use. Management algorithms have evolved to provide up-to-date, best practice care, with particular focus on individualisation of therapy.
Key Points
- Significant development has occurred in the management of type 2 diabetes over the past two decades.
- There is increasing emphasis on individualisation of both glycaemic targets and choice of therapy.
- Glycaemic targets take into account patient age, disease duration, comorbidities and patient expectations.
- With the expansion of available glucose-lowering agents, it is becoming increasingly important to consider patient comorbidities as well as the benefit and adverse effect profiles of pharmacotherapies.
- These changes have been re ected in the most recent management algorithms, most notably the ADA/EASD consensus statement of 2018.
- The most recent guidelines have an emphasis on considering patient comorbidities when choosing diabetes medications.
